Translational individualised medicine: inflammation and cancer
2022 Activity indicators
- 1 European project coordinated: REACT-EU "MITICAD-CM"- ERDF
- 7 private projects led
- 3 competitive HR contracts
- 49 publications
- IF: 174,69
- D1 publications: 3 (6 %)
- Q1 publications: 18 (37 %)
- 2 supervised doctoral theses
- Evaluators of Public Research Agencies: 2 PI.
- Members of Editorial Committees: 1 PI.
Milestones
- Competitive multicentre project in the European response against the COVID-19 pandemic financed by the Community of Madrid with FEDER funds entitled "Individualised and translational medicine in patients with COVID-19 and post-COVID: Diagnostic, therapeutic and preventive implications. Optimisation of healthcare practice in Medicine and Health Sciences in the pandemic environment (MITICAD-CM)".
- Defended doctoral thesis of a young clinical researcher with quality indexes, with more than 6 publications in JCR.
- Award of an AES22 Health Research Project entitled "Social consideration and characterisation of patterns in the abuse of opioid drugs (PI22/00653)".
- Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022; 19(2):112-134. doi: 10.1038/s41575-021-00520-7. PMID: 34703031.
- Intense sponsorship activities with more than half a million euros in clinical and translational research.
Bibliometrics
ARTICLES | ACCUM. IF | MEAN IF | ARTICLES Q1 OR Q2 | % IN Q1 OR Q2 | ARTICLES D1 | % IN D1 | |
---|---|---|---|---|---|---|---|
2018 | 9 | 38,11 | 4,23 | 11 | 122 | 2 | 22 |
2019 | 12 | 58,56 | 4,88 | 10 | 83 | 2 | 17 |
2020 | 14 | 59,21 | 4,23 | 13 | 93 | 1 | 7 |
2021 | 40 | 174,69 | 4,48 | 34 | 85 | 4 | 10 |
2022 | 49 | 307,13 | 6,27 | 42 | 86 | 3 | 6 |
124 | 637,69 | 4,82 | 110 | 89 | 12 | 10 |